Amie Kron1,2, M Elisabeth Del Giudice3, Michelle Sholzberg4,5,6, Jeannie Callum1,2,7, Christine Cserti-Gazdewich2,7,8, Vidushi Swarup4, Mary Huang9, Lanis Distefano9, Waseem Anani9, Robert Skeate7, Chantal Armali1,2, Yulia Lin10,11,12. 1. Precision Diagnostics and Therapeutics Program, Sunnybrook Health Sciences Centre, Toronto, M4N 3M5, Canada. 2. University of Toronto Quality in Utilization, Education and Safety in Transfusion (QUEST) Research Program, Toronto, Canada. 3. Department of Family and Community Medicine, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Canada. 4. Hematology Oncology Clinical Research Group, St. Michael's Hospital, Toronto, Canada. 5. Li Ka Shing Knowledge Institute, St. Michael's Hospital, Toronto, Canada. 6. Division of Hematology, Department of Medicine, St. Michael's Hospital and University of Toronto, Toronto, Canada. 7. Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Canada. 8. Laboratory Medicine Program, University Health Network, Toronto, Canada. 9. Medical Services and Hospital Relations, Canadian Blood Services, Ottawa, Canada. 10. Precision Diagnostics and Therapeutics Program, Sunnybrook Health Sciences Centre, Toronto, M4N 3M5, Canada. yulia.lin@sunnybrook.ca. 11. University of Toronto Quality in Utilization, Education and Safety in Transfusion (QUEST) Research Program, Toronto, Canada. yulia.lin@sunnybrook.ca. 12. Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Canada. yulia.lin@sunnybrook.ca.
Abstract
BACKGROUND: Iron deficiency anemia (IDA) accounts for the majority of anemia cases across the globe and can lead to impairments in both physical and cognitive functioning. Oral iron supplementation is the first line of treatment to improve the hemoglobin level for IDA patients. However, gaps still exist in understanding the appropriate dosing regimen of oral iron. The current trial proposes to evaluate the feasibility of performing this study to examine the effectiveness and side-effect profile of oral iron once daily versus every other day. METHODS: In this open-label, pilot, feasibility, randomized controlled trial, 52 outpatients over 16 years of age with IDA (defined as hemoglobin < 12.0 g/dL in females and < 13.0 g/dL in males and ferritin < 30 mcg/L) will be enrolled across two large academic hospitals. Participants are randomized in a 1:1 ratio to receive 300 mg oral ferrous sulfate (60 mg of elemental iron) either every day or every other day for 12 weeks. Participants are excluded if they are as follows: (1) pregnant and/or currently breastfeeding, (2) have a disease history that would impair response to oral iron (e.g., thalassemia, celiac disease), (3) intolerant and/or have an allergy to oral iron or vitamin C, (4) on new anticoagulants in the past 6 months, (5) received IV iron therapy in the past 12 weeks, (6) have surgery, chemotherapy, or blood donation planned in upcoming 12 weeks, (7) a creatinine clearance < 30 mL/min, or (8) hemoglobin less than 8.0 g/dL with active bleeding. The primary outcome is feasibility to enroll 52 participants in this trial over a 2-year period to determine the effectiveness of daily versus every other day oral iron supplementation on hemoglobin at 12 weeks post-initiation and side-effect profile. DISCUSSION: The results of this trial will provide additional evidence for an appropriate dosing schedule for treating patients with IDA with oral iron supplementation. Additional knowledge will be gained on how the dosing regimen of oral iron impacts quality of life and hemoglobin repletion in IDA patients. If this trial is deemed feasible, it will inform the development and implementation of a larger multicenter definitive trial. TRIAL REGISTRATION: ClinicalTrials.gov: NCT03725384 . Registered 31 October 2018.
BACKGROUND: Iron deficiency anemia (IDA) accounts for the majority of anemia cases across the globe and can lead to impairments in both physical and cognitive functioning. Oral iron supplementation is the first line of treatment to improve the hemoglobin level for IDA patients. However, gaps still exist in understanding the appropriate dosing regimen of oral iron. The current trial proposes to evaluate the feasibility of performing this study to examine the effectiveness and side-effect profile of oral iron once daily versus every other day. METHODS: In this open-label, pilot, feasibility, randomized controlled trial, 52 outpatients over 16 years of age with IDA (defined as hemoglobin < 12.0 g/dL in females and < 13.0 g/dL in males and ferritin < 30 mcg/L) will be enrolled across two large academic hospitals. Participants are randomized in a 1:1 ratio to receive 300 mg oral ferrous sulfate (60 mg of elemental iron) either every day or every other day for 12 weeks. Participants are excluded if they are as follows: (1) pregnant and/or currently breastfeeding, (2) have a disease history that would impair response to oral iron (e.g., thalassemia, celiac disease), (3) intolerant and/or have an allergy to oral iron or vitamin C, (4) on new anticoagulants in the past 6 months, (5) received IV iron therapy in the past 12 weeks, (6) have surgery, chemotherapy, or blood donation planned in upcoming 12 weeks, (7) a creatinine clearance < 30 mL/min, or (8) hemoglobin less than 8.0 g/dL with active bleeding. The primary outcome is feasibility to enroll 52 participants in this trial over a 2-year period to determine the effectiveness of daily versus every other day oral iron supplementation on hemoglobin at 12 weeks post-initiation and side-effect profile. DISCUSSION: The results of this trial will provide additional evidence for an appropriate dosing schedule for treating patients with IDA with oral iron supplementation. Additional knowledge will be gained on how the dosing regimen of oral iron impacts quality of life and hemoglobin repletion in IDA patients. If this trial is deemed feasible, it will inform the development and implementation of a larger multicenter definitive trial. TRIAL REGISTRATION: ClinicalTrials.gov: NCT03725384 . Registered 31 October 2018.
Authors: Paul A Harris; Robert Taylor; Robert Thielke; Jonathon Payne; Nathaniel Gonzalez; Jose G Conde Journal: J Biomed Inform Date: 2008-09-30 Impact factor: 6.317
Authors: Zuguo Mei; Mary E Cogswell; Anne C Looker; Christine M Pfeiffer; Sarah E Cusick; David A Lacher; Laurence M Grummer-Strawn Journal: Am J Clin Nutr Date: 2011-03-23 Impact factor: 7.045
Authors: Nicole U Stoffel; Colin I Cercamondi; Gary Brittenham; Christophe Zeder; Anneke J Geurts-Moespot; Dorine W Swinkels; Diego Moretti; Michael B Zimmermann Journal: Lancet Haematol Date: 2017-10-09 Impact factor: 18.959
Authors: Sarah Acaster; Rene Dickerhoof; Kendra DeBusk; Kristine Bernard; William Strauss; Lee F Allen Journal: Health Qual Life Outcomes Date: 2015-05-17 Impact factor: 3.186
Authors: Nicole U Stoffel; Christophe Zeder; Gary M Brittenham; Diego Moretti; Michael B Zimmermann Journal: Haematologica Date: 2019-08-14 Impact factor: 9.941